- Home
- SLGL vs IBIO Comparison
SLGL vs IBIO Comparison
Compare SLGL & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- IBIO
- Stock Information
- Founded
- SLGL 1997
- IBIO 2008
- Country
- SLGL Israel
- IBIO United States
- Employees
- SLGL N/A
- IBIO N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- IBIO Health Care
- Exchange
- SLGL Nasdaq
- IBIO Nasdaq
- Market Cap
- SLGL 19.3M
- IBIO 15.9M
- IPO Year
- SLGL 2018
- IBIO N/A
- Fundamental
- Price
- SLGL $8.14
- IBIO $0.81
- Analyst Decision
- SLGL Buy
- IBIO Strong Buy
- Analyst Count
- SLGL 1
- IBIO 3
- Target Price
- SLGL $40.00
- IBIO $4.87
- AVG Volume (30 Days)
- SLGL 25.4K
- IBIO 5.4M
- Earning Date
- SLGL 08-15-2025
- IBIO 05-02-2025
- Dividend Yield
- SLGL N/A
- IBIO N/A
- EPS Growth
- SLGL N/A
- IBIO N/A
- EPS
- SLGL N/A
- IBIO N/A
- Revenue
- SLGL $12,103,000.00
- IBIO $375,000.00
- Revenue This Year
- SLGL N/A
- IBIO $36.00
- Revenue Next Year
- SLGL $31.17
- IBIO N/A
- P/E Ratio
- SLGL N/A
- IBIO N/A
- Revenue Growth
- SLGL 603.66
- IBIO 650.00
- 52 Week Low
- SLGL $3.34
- IBIO $0.64
- 52 Week High
- SLGL $16.50
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- SLGL 63.80
- IBIO 47.34
- Support Level
- SLGL $6.96
- IBIO $0.71
- Resistance Level
- SLGL $7.48
- IBIO $0.87
- Average True Range (ATR)
- SLGL 0.28
- IBIO 0.08
- MACD
- SLGL 0.07
- IBIO 0.02
- Stochastic Oscillator
- SLGL 95.88
- IBIO 37.39
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.